CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Therapeutics (Nasdaq:CAMP) granted non-qualified stock options to three new employees under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

CAMP4 Therapeutics (Nasdaq:CAMP) granted non-qualified stock options to three new employees under Nasdaq Listing Rule 5635(c)(4). The inducement awards cover an aggregate 39,000 shares at an exercise price of $3.96 per share, equal to the June 15, 2026 closing price.

The options have a 10-year term and vest over four years: 25% after one year of employment, then the remainder in 36 equal monthly installments, subject to continued service. The grants are issued under CAMP4’s 2026 Inducement Plan and related stock option agreements.

Argus Jun 22 session

+1.69% close to close Open Argus

Details

News Market Reaction – CAMP

In the Jun 22 session, CAMP gained 1.69%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details 39,000 inducement stock options granted under Nasdaq rules at an exercise ...

Analysis

This announcement details 39,000 inducement stock options granted under Nasdaq rules at an exercise price of $3.96, a routine hiring tool. Prior similar grants produced only modest stock moves, though dilution from equity programs and the shelf remains a background risk to monitor.

Key Figures

Inducement options granted: 39,000 shares Number of new hires: 3 employees Exercise price: $3.96 per share +4 more

Inducement options granted

39,000 shares

Aggregate non-qualified stock options to three new employees on June 15, 2026

Number of new hires

3 employees

Recipients of inducement non-qualified stock options

Exercise price

$3.96 per share

Equal to CAMP4’s common stock closing price on the June 15, 2026 grant date

Option term

10 years

Duration of each non-qualified stock option under the inducement grants

Vesting period

4 years

Inducement options vest over four years, subject to continued service

Initial vesting cliff

25% at 1 year

First tranche vests on the one-year anniversary of employment start date

Subsequent vesting schedule

36 monthly installments

Remaining option shares vest in equal monthly installments after year one

Historical Context

5 past events · Latest: May 21

5 events

1. May 21

   Inducement grant

   24h Move

   +2.5%

   Single new-hire option grant under Nasdaq inducement rule with 4-year vesting.

2. May 14

   Preclinical data

   24h Move

   -2.7%

   New preclinical CMP-002 data showing improved seizure metrics in SYNGAP1 model.

3. May 07

   Earnings & update

   24h Move

   +2.8%

   Q1 2026 financials with cash runway into 2028 and CMP-002 regulatory progress.

4. Apr 28

   Scientific preprint

   24h Move

   -3.8%

   regRNA profiling preprint and identification of CMP-002 as lead SYNGAP1 candidate.

5. Apr 17

   Inducement grants

   24h Move

   +0.5%

   Prior multi-employee inducement option grants with 10-year term and 4-year vest.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, nasdaq listing rule 5635(c)(4), exercise price, inducement grants

4 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 39,000 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"an exercise price per share of $3.96, which is equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

inducement grants regulatory

"The Inducement Grants each have a ten-year term and an exercise price"

Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,000 shares of the Company’s common stock to three newly hired employees of the Company, each as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).

The Inducement Grants each have a ten-year term and an exercise price per share of $3.96, which is equal to the closing price of CAMP4’s common stock as of the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service with CAMP4 through the applicable vesting dates. Each Inducement Grant was granted pursuant to, and is subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable non-qualified stock option agreement.

About CAMP4 Therapeutics 
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform^® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.

Contacts

Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com

Media:
Sofia Bermudez
LifeSci Communications
sbermudez@lifescicomms.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement stock option grants did CAMP4 Therapeutics (NASDAQ:CAMP) announce on June 19, 2026?

CAMP4 Therapeutics announced non-qualified stock options for an aggregate 39,000 shares as inducement grants to three new employees. According to CAMP4, these options were approved on June 15, 2026 under Nasdaq Listing Rule 5635(c)(4) as material to each employee’s hiring.

What is the exercise price of the CAMP4 Therapeutics (CAMP) inducement options granted June 15, 2026?

The inducement options have an exercise price of $3.96 per share. According to CAMP4, this price equals the closing price of CAMP4 common stock on the June 15, 2026 grant date used for these non-qualified stock option awards.

How do CAMP4 Therapeutics (CAMP) inducement stock options vest for the three new employees?

The inducement options vest over four years. According to CAMP4, 25% of each grant vests on the one-year anniversary of the employee’s first day, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service.

What is the term length of the CAMP4 Therapeutics (CAMP) inducement stock options?

Each inducement stock option has a 10-year term from the grant date. According to CAMP4, the non-qualified options were granted on June 15, 2026 and remain exercisable during this period, subject to vesting and the applicable stock option agreement.

Under what plan were the CAMP4 Therapeutics (CAMP) June 2026 inducement grants issued?

The June 2026 inducement grants were issued under CAMP4’s 2026 Inducement Plan. According to CAMP4, each non-qualified stock option is also governed by an applicable stock option agreement outlining specific terms and conditions for the new employee recipients.